OOIR: Observatory of International Research

Papers

(The median citation count of JAMA Cardiology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19)	1630
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes	723
Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases	652
Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military	411
Prevalence of Clinical and Subclinical Myocarditis in Competitive Athletes With Recent SARS-CoV-2 Infection	243
Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination	242
Prevalence of Inflammatory Heart Disease Among Professional Athletes With Prior COVID-19 Infection Who Received Systematic Return-to-Play Cardiac Screening	208
Utility of a Deep-Learning Algorithm to Guide Novices to Acquire Echocardiograms for Limited Diagnostic Use	207
Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome	165
Evaluation for Myocarditis in Competitive Student Athletes Recovering From Coronavirus Disease 2019 With Cardiac Magnetic Resonance Imaging	161
TET2-Driven Clonal Hematopoiesis and Response to Canakinumab	156
Coronavirus Disease 2019 and the Athletic Heart	155
Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children	146
Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure—Optimizing Therapy With the Need for Speed	146
Evolving Trends in Adult Heart Transplant With the 2018 Heart Allocation Policy Change	144
Association of Troponin Levels With Mortality in Italian Patients Hospitalized With Coronavirus Disease 2019	142
Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction	141
Use of Machine Learning Models to Predict Death After Acute Myocardial Infarction	138
Association of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis	136
Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction	135
SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents	132
Lipoprotein(a) and its Significance in Cardiovascular Disease	130
Screening for Atrial Fibrillation in the Older Population	124
Association of Adverse Childhood Experiences With Cardiovascular Disease Later in Life	120
Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction	117

Outcomes for Out-of-Hospital Cardiac Arrest in the United States During the Coronavirus Disease 2019 Pandemic	117
One-Year Outcomes of Mitral Valve-in-Valve Using the SAPIEN 3 Transcatheter Heart Valve	115
National Trends in Heart Failure Hospitalizations and Readmissions From 2010 to 2017	115
Mechanical Complications of Acute Myocardial Infarction	111
Case Rates, Treatment Approaches, and Outcomes in Acute Myocardial Infarction During the Coronavirus Disease 2019 Pandemic	105
Association Between High-Density Lipoprotein Cholesterol Levels and Adverse Cardiovascular Outcomes in High-risk Populations	102
Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US	102
Association of Lipid, Inflammatory, and Metabolic Biomarkers With Age at Onset for Incident Coronary Heart Disease in Women	98
Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction	93
Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction	91
Assessment of Catheter Ablation or Antiarrhythmic Drugs for First-line Therapy of Atrial Fibrillation	90
Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine–Induced Immune Thrombotic Thrombocytopenia With Cerebral Venous Sinus Thrombosis	89
Association Between Cumulative Low-Density Lipoprotein Cholesterol Exposure During Young Adulthood and Middle Age and Risk of Cardiovascular Events	88
High-Throughput Precision Phenotyping of Left Ventricular Hypertrophy With Cardiovascular Deep Learning	87
Early-Onset Atrial Fibrillation and the Prevalence of Rare Variants in Cardiomyopathy and Arrhythmia Genes	87
Early Mortality in Type A Acute Aortic Dissection	86
Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor–Associated Myocarditis	84
Myocarditis Occurring After Immunization With mRNA-Based COVID-19 Vaccines	83
Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction	82
Association of Statin Treatment With Progression of Coronary Atherosclerotic Plaque Composition	82
Use of Artificial Intelligence and Deep Neural Networks in Evaluation of Patients With Electrocardiographically Concealed Long QT Syndrome From the Surface 12-Lead Electrocardiogram	80
Posttraumatic Stress Disorder and Cardiovascular Disease	77
Performance of a Convolutional Neural Network and Explainability Technique for 12-Lead Electrocardiogram Interpretation	76
Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction	76
Remote Optimization of Guideline-Directed Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction	75
Association of Adverse Pregnancy Outcomes With Risk of Atherosclerotic Cardiovascular Disease in Postmenopausal Women	73
Effectiveness of Home-Based Mobile Guided Cardiac Rehabilitation as Alternative Strategy for Nonparticipation in Clinic-Based Cardiac Rehabilitation Among Elderly Patients in Europe	71
Coronary Angiography After Cardiac Arrest Without ST Segment Elevation	68
Association of Age With the Diagnostic Value of Coronary Artery Calcium Score for Ruling Out Coronary Stenosis in Symptomatic Patients	67
Short-term and Long-term Feasibility, Safety, and Efficacy of High-Intensity Interval Training in Cardiac Rehabilitation	67
Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure	67
Fundamental Pathobiology of Coronary Atherosclerosis and Clinical Implications for Chronic Ischemic Heart Disease Management—The Plaque Hypothesis	67
Interpretation of the Seattle Angina Questionnaire as an Outcome Measure in Clinical Trials and Clinical Care	66
Diagnosis of Heart Failure With Preserved Ejection Fraction Among Patients With Unexplained Dyspnea	65
Survival on the Heart Transplant Waiting List	65
Contemporaneous Comparison of Outcomes Among Patients Implanted With a Leadless vs Transvenous Single-Chamber Ventricular Pacemaker	64
Clinical Utility of Lipoprotein(a) and LPA Genetic Risk Score in Risk Prediction of Incident Atherosclerotic Cardiovascular Disease	63
Assessing the Risks of Bleeding vs Thrombotic Events in Patients at High Bleeding Risk After Coronary Stent Implantation	62
Self-expanding Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients	62
Assessment of Neutrophil Extracellular Traps in Coronary Thrombus of a Case Series of Patients With COVID-19 and Myocardial Infarction	60
Temporal Association Between Episodes of Atrial Fibrillation and Risk of Ischemic Stroke	60
Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease	60
Effect of Exercise Training on Ambulatory Blood Pressure Among Patients With Resistant Hypertension	59
Stress Myocardial Perfusion Imaging vs Coronary Computed Tomographic Angiography for Diagnosis of Invasive Vessel-Specific Coronary Physiology	58
Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk	58
Catheter-Directed Thrombolysis vs Anticoagulation in Patients With Acute Intermediate-High–risk Pulmonary Embolism	57
Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy	57
Interventions to Mitigate Risk of Cardiovascular Disease After Adverse Pregnancy Outcomes	56
Assessment of Coronary Artery Calcium Scoring to Guide Statin Therapy Allocation According to Risk-Enhancing Factors	55
Sex Differences in Procedural Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion	55

Coronavirus Disease 2019 (COVID-19) and the Heart—Is Heart Failure the Next Chapter?	55
Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event	54
Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome	54
Magnetic Resonance Imaging in Patients With Cardiac Implantable Electronic Devices With Abandoned Leads	54
Association of Effective Regurgitation Orifice Area to Left Ventricular End-Diastolic Volume Ratio With Transcatheter Mitral Valve Repair Outcomes	54
Emergency vs Delayed Coronary Angiogram in Survivors of Out-of-Hospital Cardiac Arrest	53
Effect of Personalized Accelerated Pacing on Quality of Life, Physical Activity, and Atrial Fibrillation in Patients With Preclinical and Overt Heart Failure With Preserved Ejection Fraction	53
Association of Diet Quality With Prevalence of Clonal Hematopoiesis and Adverse Cardiovascular Events	53
Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Hear	52
Long-term Results of Differentiated Anatomic Reconstruction of Bicuspid Aortic Valves	50
Efficacy of Telmisartan to Slow Growth of Small Abdominal Aortic Aneurysms	49
Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction	49
Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction	48
Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US	47
Racial, Ethnic, and Socioeconomic Disparities in Access to Transcatheter Aortic Valve Replacement Within Major Metropolitan Areas	47
Differences in Long-term Outcomes After Coronary Artery Bypass Grafting Using Single vs Multiple Arterial Grafts and the Association With Sex	45
Association of Sitting Time With Mortality and Cardiovascular Events in High-Income, Middle-Income, and Low-Income Countries	45
Skeletonized vs Pedicled Internal Mammary Artery Graft Harvesting in Coronary Artery Bypass Surgery	45
Demographic and Regional Trends of Heart Failure–Related Mortality in Young Adults in the US, 1999-2019	45
Structural Valve Deterioration After Self-Expanding Transcatheter or Surgical Aortic Valve Implantation in Patients at Intermediate or High Risk	45
Combined Cardiac Fluorodeoxyglucose–Positron Emission Tomography/Magnetic Resonance Imaging Assessment of Myocardial Injury in Patients Who Recently Recovered From COVID-19	44
Percutaneous Intramyocardial Septal Radiofrequency Ablation in Patients With Drug-Refractory Hypertrophic Obstructive Cardiomyopathy	44
Association of Socioeconomic Disadvantage With Long-term Mortality After Myocardial Infarction	42
Association of Left Ventricular Systolic Dysfunction Among Carriers of Truncating Variants in Filamin C With Frequent Ventricular Arrhythmia and End-stage Heart Failure	42
Assessing the Role of Rare Genetic Variation in Patients With Heart Failure	42
Association of Damaging Variants in Genes With Increased Cancer Risk Among Patients With Congenital Heart Disease	40
Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials	40
Apolipoprotein B vs Low-Density Lipoprotein Cholesterol and Non–High-Density Lipoprotein Cholesterol as the Primary Measure of Apolipoprotein B Lipoprotein-Related Risk	40
Association Between Reproductive Life Span and Incident Nonfatal Cardiovascular Disease	39
Predictive Utility of a Coronary Artery Disease Polygenic Risk Score in Primary Prevention	39
Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control	39
Association of Circulating Monocyte Chemoattractant Protein–1 Levels With Cardiovascular Mortality	39
Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction	39
Results of a Remotely Delivered Hypertension and Lipid Program in More Than 10 000 Patients Across a Diverse Health Care Network	38
Comparison of Long-term Clinical Outcomes of Skeletonized vs Pedicled Internal Thoracic Artery Harvesting Techniques in the Arterial Revascularization Trial	38
A Simple Score to Identify Increased Risk of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction	38
Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With β-Blockers	38
Vigorous Exercise in Patients With Hypertrophic Cardiomyopathy	38
Cardiovascular Magnetic Resonance Imaging Phenotypes and Long-term Outcomes in Patients With Suspected Cardiac Sarcoidosis	38
Clinical and Functional Characterization of Ryanodine Receptor 2 Variants Implicated in Calcium-Release Deficiency Syndrome	37
Individualized Studies of Triggers of Paroxysmal Atrial Fibrillation	37
Association of Rare Genetic Variants and Early-Onset Atrial Fibrillation in Ethnic Minority Individuals	37
Associations of Adiposity, Circulating Protein Biomarkers, and Risk of Major Vascular Diseases	36
Association of Posttraumatic Stress Disorder and Incident Ischemic Heart Disease in Women Veterans	36
Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines	36
Machine Learning–Based Models Incorporating Social Determinants of Health vs Traditional Models for Predicting In-Hospital Mortality in Patients With Heart Failure	36
Long-term Survival After Out-of-Hospital Cardiac Arrest	36
Association of Pediatric Obstructive Sleep Apnea With Elevated Blood Pressure and Orthostatic Hypertension in Adolescence	35
Association of Differences in Treatment Intensification, Missed Visits, and Scheduled Follow-up Interval With Racial or Ethnic Disparities in Blood Pressure Control	35
Association of Atrial Fibrillation Burden With Health-Related Quality of Life After Atrial Fibrillation Ablation	35
Trends in the Prevalence of Self-reported Heart Failure by Race/Ethnicity and Age From 2001 to 2016	35
Long-term Benefits and Harms Associated With Genetic Cholesteryl Ester Transfer Protein Deficiency in the General Population	33
Association of Echocardiographic Left Ventricular End-Systolic Volume and Volume-Derived Ejection Fraction With Outcome in Asymptomatic Chronic Aortic Regurgitation	33
Genetic Risk Factors Associated With Preeclampsia and Hypertensive Disorders of Pregnancy	33
Objective Risk Assessment vs Standard Care for Acute Coronary Syndromes	33
Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease	33
Routine Ultrasonography Guidance for Femoral Vascular Access for Cardiac Procedures	33
Skeletal Muscle Mitochondrial Respiration and Exercise Intolerance in Patients With Heart Failure With Preserved Ejection Fraction	33
Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention	32
Assessment of Artificial Intelligence in Echocardiography Diagnostics in Differentiating Takotsubo Syndrome From Myocardial Infarction	32
Assessment of the Diagnostic Yield of Combined Cardiomyopathy and Arrhythmia Genetic Testing	32
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction	32
Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction	31
Blood DNA Methylation and Incident Coronary Heart Disease	31
State of the Nation’s Cardiovascular Health and Targeting Health Equity in the United States	31
Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials	31
Quality of Life in Patients With Heart Failure With Recovered Ejection Fraction	30
Remote Cardiac Monitoring in Patients With Heart Failure	30
Derivation and Validation of a 4-Level Clinical Pretest Probability Score for Suspected Pulmonary Embolism to Safely Decrease Imaging Testing	30
Genomic Autopsy of Sudden Deaths in Young Individuals	30
Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction	30
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes	29
Food Insecurity Among Individuals With Cardiovascular Disease and Cardiometabolic Risk Factors Across Race and Ethnicity in 1999-2018	29
Guideline Update on Indications for Transcatheter Aortic Valve Implantation Based on the 2020 American College of Cardiology/American Heart Association Guidelines for Management of Valvular Heart Dise	29
Alerting Clinicians to 1-Year Mortality Risk in Patients Hospitalized With Heart Failure	29
Outcomes Associated With Catheter Ablation of Ventricular Tachycardia in Patients With Cardiac Sarcoidosis	29
Associations of High-Sensitivity Troponin and Natriuretic Peptide Levels With Outcomes After Intensive Blood Pressure Lowering	29
Association of Rurality With Risk of Heart Failure	29
Association of Mortality With Aortic Stenosis Severity in Outpatients	28
Association of Mitral Annular Disjunction With Cardiovascular Outcomes Among Patients With Marfan Syndrome	28

Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction	28
Rare and Common Genetic Variation Underlying the Risk of Hypertrophic Cardiomyopathy in a National Biobank	28
Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines	28
Sex-Related Disparities in Cardiovascular Health Care Among Patients With Premature Atherosclerotic Cardiovascular Disease	28
Association of Non–High-Density Lipoprotein Cholesterol Measured in Adolescence, Young Adulthood, and Mid-Adulthood With Coronary Artery Calcification Measured in Mid-Adulthood	28
Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US	28
Association of Systolic Blood Pressure Elevation With Disproportionate Left Ventricular Remodeling in Very Preterm-Born Young Adults	27
Mortality Among Patients With Early-Onset Atrial Fibrillation and Rare Variants in Cardiomyopathy and Arrhythmia Genes	26
Association of Financial Hardship Because of Medical Bills With Adverse Outcomes Among Families of Children With Congenital Heart Disease	26
Frailty and Effects of a Multidomain Physical Rehabilitation Intervention Among Older Patients Hospitalized for Acute Heart Failure	26
Evaluation of Stress Cardiac Magnetic Resonance Imaging in Risk Reclassification of Patients With Suspected Coronary Artery Disease	26
Association of Genetic West African Ancestry, Blood Pressure Response to Therapy, and Cardiovascular Risk Among Self-reported Black Individuals in the Systolic Blood Pressure Reduction Intervention Tr	26
Long-term Clinical and Echocardiographic Outcomes in Young and Middle-aged Adults Undergoing the Ross Procedure	26
Cardiovascular Biomarkers in the Early Discrimination of Type 2 Myocardial Infarction	26
Return to Play for Athletes After COVID-19 Infection	26
Association of Global Longitudinal Strain With Clinical Status and Mortality in Patients With Chronic Heart Failure	26
Association of Race and Ethnicity With Oral Anticoagulation and Associated Outcomes in Patients With Atrial Fibrillation	26
Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure	25
Evaluation of Quality of Care for US Veterans With Recent-Onset Heart Failure With Reduced Ejection Fraction	25
Role of Coronary Artery Calcium Testing for Risk Assessment in Primary Prevention of Atherosclerotic Cardiovascular Disease	25
Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction	25
Sex and Race Differences in N-Terminal Pro–B-type Natriuretic Peptide Concentration and Absolute Risk of Heart Failure in the Community	25
Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption	25
Association of Smoking With Postprocedural Complications Following Open and Endovascular Interventions for Intermittent Claudication	25
Association of Left Ventricular Remodeling Assessment by Cardiac Magnetic Resonance With Outcomes in Patients With Chronic Aortic Regurgitation	25
Prevalence and Disease Spectrum of Extracoronary Arterial Abnormalities in Spontaneous Coronary Artery Dissection	25
Effect of Transcutaneous Magnetic Stimulation in Patients With Ventricular Tachycardia Storm	25
High-Sensitivity Cardiac Troponin Concentrations at Presentation in Patients With ST-Segment Elevation Myocardial Infarction	25
Effect of Nudges to Clinicians, Patients, or Both to Increase Statin Prescribing	24
Metabolomic Analysis of Coronary Heart Disease in an African American Cohort From the Jackson Heart Study	24
Clinical Presentation and Short- and Long-term Outcomes in Patients With Isolated Distal Deep Vein Thrombosis vs Proximal Deep Vein Thrombosis in the RIETE Registry	24
Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants	23
Effectiveness of Systematic Echocardiographic Screening for Rheumatic Heart Disease in Nepalese Schoolchildren	23
Effect of Smartphone Dispatch of Volunteer Responders on Automated External Defibrillators and Out-of-Hospital Cardiac Arrests	23
Fibrillar Collagen Variants in Spontaneous Coronary Artery Dissection	23
Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation	23
Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US	22
Effectiveness of a Text-Based Gamification Intervention to Improve Physical Activity Among Postpartum Individuals With Hypertensive Disorders of Pregnancy	22
Effect of Goal-Setting Approaches Within a Gamification Intervention to Increase Physical Activity Among Economically Disadvantaged Adults at Elevated Risk for Major Adverse Cardiovascular Events	22
Circumferential Pulmonary Vein Isolation With vs Without Additional Low-Voltage-Area Ablation in Older Patients With Paroxysmal Atrial Fibrillation	22
Prevalence and Trends of Coronary Heart Disease in the United States, 2011 to 2018	21
Preterm Delivery and Long-term Risk of Hypertension in Women	21
Sex Differences in Atrial Fibrillation Risk	21
Association of Thoracic Aortic Aneurysm Size With Long-term Patient Outcomes	21
Exercise Capacity in Young Adults Born Small for Gestational Age	21
Association of Plaque Location and Vessel Geometry Determined by Coronary Computed Tomographic Angiography With Future Acute Coronary Syndrome–Causing Culprit Lesions	21
Viability and Outcomes With Revascularization or Medical Therapy in Ischemic Ventricular Dysfunction	21
Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020	21
Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy	20
Comparison of an Initial Risk-Based Testing Strategy vs Usual Testing in Stable Symptomatic Patients With Suspected Coronary Artery Disease	20
Association of Low-Dose Triple Combination Therapy With Therapeutic Inertia and Prescribing Patterns in Patients With Hypertension	20
Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice	20
Practical Recommendations on Quantifying and Interpreting Treatment Effects in the Presence of Terminal Competing Risks	20
Association Between Early Left Ventricular Ejection Fraction Improvement After Transcatheter Aortic Valve Replacement and 5-Year Clinical Outcomes	20
Coronary Artery Spasm During Pulsed Field vs Radiofrequency Catheter Ablation of the Mitral Isthmus	20
Association of COVID-19 Vaccination With Risk of COVID-19 Infection, Hospitalization, and Death in Heart Transplant Recipients	20
Mendelian Randomization as a Tool for Cardiovascular Research	20
Association of Titin Variations With Late-Onset Dilated Cardiomyopathy	20
Performance of the European Society of Cardiology 0/1-Hour Algorithm With High-Sensitivity Cardiac Troponin T Among Patients With Known Coronary Artery Disease	20
Incremental Benefits of Machine Learning—When Do We Need a Better Mousetrap?	19
Association of Pathogenic DNA Variants Predisposing to Cardiomyopathy With Cardiovascular Disease Outcomes and All-Cause Mortality	19
Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre–Heart Failure With Preserved Ejection Fraction	19
Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid–Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout	19
Association of Myocardial Blood Flow Reserve With Adverse Left Ventricular Remodeling in Patients With Aortic Stenosis	19
Association of Plasma High-Density Lipoprotein Cholesterol Level With Risk of Fractures in Healthy Older Adults	18
Association of Long-term Change in N-Terminal Pro–B-Type Natriuretic Peptide With Incident Heart Failure and Death	18
A Combined Echocardiography Approach for the Diagnosis of Cancer Therapy–Related Cardiac Dysfunction in Women With Early-Stage Breast Cancer	18
Association of Left Atrial Strain With Ischemic Stroke Risk in Older Adults	18
Genetic Inhibition ofPCSK9and Liver Function	18
Quality of Care and Outcomes Among Medicare Advantage vs Fee-for-Service Medicare Patients Hospitalized With Heart Failure	18
Association of Left Ventricular Systolic Function With Incident Heart Failure in Late Life	18
Comparative Effectiveness of Percutaneous Microaxial Left Ventricular Assist Device vs Intra-Aortic Balloon Pump or No Mechanical Circulatory Support in Patients With Cardiogenic Shock	18
Association of Complement and MAPK Activation With SARS-CoV-2–Associated Myocardial Inflammation	18
Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease Among US Adults With Diabetes	18
Potential Role and Limitations of Estimated Glomerular Filtration Rate Slope Assessment in Cardiovascular Trials	18
Evaluation of Risk-Adjusted Home Time After Hospitalization for Heart Failure as a Potential Hospital Performance Metric	17
Complete Revascularization vs Culprit Lesion–Only Percutaneous Coronary Intervention for Angina-Related Quality of Life in Patients With ST-Segment Elevation Myocardial Infarction	17
Trends in Transcatheter vs Surgical Mitral Valve Repair Among Medicare Beneficiaries, 2012 to 2019	17
Cardiovascular Disease Risk Assessment Using Traditional Risk Factors and Polygenic Risk Scores in the Million Veteran Program	16
Optimizing Training Response for Women in Cardiac Rehabilitation	16
Diagnostic and Prognostic Value of Stress Cardiovascular Magnetic Resonance Imaging in Patients With Known or Suspected Coronary Artery Disease	16
Use of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagonlike Peptide-1 Receptor Agonists in Patients With Diabetes and Cardiovascular Disease in Community Practice	16
Association of Dual Eligibility for Medicare and Medicaid With Heart Failure Quality and Outcomes Among Get With The Guidelines–Heart Failure Hospitals	16
External Support for Saphenous Vein Grafts in Coronary Artery Bypass Surgery	16
Measured Blood Pressure, Genetically Predicted Blood Pressure, and Cardiovascular Disease Risk in the UK Biobank	16
Coronary Atherosclerotic Plaque Activity and Future Coronary Events	16
Effect of a Self-care Intervention on 90-Day Outcomes in Patients With Acute Heart Failure Discharged From the Emergency Department	16
Analysis of Respiratory Fluoroquinolones and the Risk of Sudden Cardiac Death Among Patients Receiving Hemodialysis	16
Association of Novel Locus With Rheumatic Heart Disease in Black African Individuals	16
Subclinical Leaflet Thrombosis and Anticoagulation After Transcatheter Aortic Valve Replacement	16
Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction	16
Association of Interleukin 6 Inhibition With Ziltivekimab and the Neutrophil-Lymphocyte Ratio	16
Association of N-Terminal Pro–Brain Natriuretic Peptide Concentration in Early Pregnancy With Development of Hypertensive Disorders of Pregnancy and Future Hypertension	16
Trends in 10-Year Outcomes Among Medicare Beneficiaries Who Survived an Acute Myocardial Infarction	16
Associations Between Carotid Artery Plaque Burden, Plaque Characteristics, and Cardiovascular Events	15